Search research articles
Contact Us
Filters
Showing results (151-160 of 231) with videos related to
Page
of 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Matthew P Goetz, Erika P Hamilton, Mario Campone, et al.
Molecular Oncology
|
October 1, 2015
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
Paolo Nuciforo, Sheeno Thyparambil, Claudia Aura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>-</sup> Advanced Breast Cancer
Aditya Bardia, Shanu Modi, Mafalda Oliveira, et al.
Breast Cancer Research : BCR
|
June 12, 2023
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Peter Schmid, Javier Cortes, Ana Joaquim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2009
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study
Javier Cortes, Serena Di Cosimo, Miguel A Climent, et al.
CA: a Cancer Journal for Clinicians
|
February 19, 2020
Enhancing global access to cancer medicines
Javier Cortes, Jose Manuel Perez-García, Antonio Llombart-Cussac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2010
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
Javier Cortes, Linda Vahdat, Joanne L Blum, et al.
Lancet (London, England)
|
March 8, 2011
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes, Joyce O'Shaughnessy, David Loesch, et al.
JCO Global Oncology
|
February 2, 2021
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology
Concetta Elisa Onesti, Marco Tagliamento, Giuseppe Curigliano, et al.
Annals of Surgical Oncology
|
February 25, 2026
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study
Sherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Page
of 24
Search research articles
Search
Showing results (151-160 of 231) with videos related to
Sort By:
Page
of 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Matthew P Goetz, Erika P Hamilton, Mario Campone, et al.
Molecular Oncology
|
October 1, 2015
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
Paolo Nuciforo, Sheeno Thyparambil, Claudia Aura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>-</sup> Advanced Breast Cancer
Aditya Bardia, Shanu Modi, Mafalda Oliveira, et al.
Breast Cancer Research : BCR
|
June 12, 2023
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Peter Schmid, Javier Cortes, Ana Joaquim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2009
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study
Javier Cortes, Serena Di Cosimo, Miguel A Climent, et al.
CA: a Cancer Journal for Clinicians
|
February 19, 2020
Enhancing global access to cancer medicines
Javier Cortes, Jose Manuel Perez-García, Antonio Llombart-Cussac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2010
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
Javier Cortes, Linda Vahdat, Joanne L Blum, et al.
Lancet (London, England)
|
March 8, 2011
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes, Joyce O'Shaughnessy, David Loesch, et al.
JCO Global Oncology
|
February 2, 2021
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology
Concetta Elisa Onesti, Marco Tagliamento, Giuseppe Curigliano, et al.
Annals of Surgical Oncology
|
February 25, 2026
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study
Sherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Page
of 24